NCT03145025已完成不适用
An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- The primary safety endpoint is change from baseline in endothelial cell density (ECD) in the study eye one year following implantation.
研究概览
简要总结
An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant
详细描述
This is a prospective, multicenter, open-label, single arm, observational evaluation of the corneal ECD change from baseline for subjects having the Retisert FA drug delivery system (0.59 mg) surgically implanted in the ocular vitreous chamber of at least 1 previously unimplanted eye for at least 1 year.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are scheduled for surgical placement of a Retisert fluocinolone acetonide (FA) intravitreal implant in a previously unimplanted eye.
- •Are able and willing to comply with all treatment and follow up/study procedures.
- •Able and willing to provide informed consent or, for subjects 12-18 years of age, have the ability to understand and provide assent (when applicable) and whose parent/legally authorized representative has the ability to understand and provide written informed consent on the Institutional Review Board (IRB) approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations.
- •For female subjects:
- •Note: Should a subject conceive during the study, the pregnancy should be reported as soon as possible to the study Medical Monitor and Promedica International within 24 hours. The pregnancy will be followed up to term. The subject will continue in the studyregardless if pregnancy is reported on an AE/SAE form. If an Investigator becomes aware of a post study pregnancy 30 days after the study exit visit while Fluocinolone Acetonide Implant remains in the subject's study eye, then it should be reported as a post-marketing report
排除标准
- •Has previously, concurrently or anticipated enrollment in Bausch & Lomb study 440, titled, "An Observational Bilateral Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant for at Least One Year."
- •Has severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study, based on the judgment of the Investigator.
- •Has participated in an ophthalmic drug or device research study within 30 days prior to Screening (Visit 1, Day -30 to -1) in this study
- •Is monocular (unable to detect hand motion at 6 feet in 1 eye).
- •Has a known corneal dystrophy or corneal transplant.
- •Has a history of ocular surgery in the eye scheduled for implant surgery, including laser procedures, within the 30 days prior to Screening (Visit 1, Day -30 to -1).
- •Had any type of intraocular drug delivery implant (eg, Retisert, Ozurdex [dexamethasone intravitreal implant]) in the study eye.
结局指标
主要结局
The primary safety endpoint is change from baseline in endothelial cell density (ECD) in the study eye one year following implantation.
时间窗: 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Qualitative and Quantitative Endothelium Changes After Cataract Surgery: Ultrasound Phacoemulsification vs Nanolaser TechniqueEffect of Cataract Surgery on Corneal Endothelium About 2 TechniquesNCT05886283University Tunis El Manar74
已完成
不适用
Changes of the Corneal Endothelial Cell Count After Artisan Phakic Intraocular Lens ImplantationHigh MyopiaNCT03266354Assiut University12
已完成
不适用
Corneal Endothelium Evaluation After Phacoemulsification in Diabetec and Non-diabetic Patients With PseudoexfoliationPseudoexfoliationNCT04965168Minia University61
Unknown
不适用
Endothelial Changes in Pseudoexfoliation SyndromeEndothelial Cell Loss, CornealNCT05194891Assiut University100
已完成
不适用
Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent ImplantationGlaucomaEndothelial Cell Loss, CornealNCT04547036Paracelsus Medical University129